External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>GSS put in a solid sales performance in H123, beating our forecasts.</li><li>However, the delayed timeline, announced in January, for submission of the application for clearance of the Enteric Protozoan test kit in the US was disappointing.</li><li>The FDA submission is now expected before the end of April vs AGM guidance targeting December and our assumption of Q1 CY23.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

GSS put in a solid sales performance in H123, beating our forecasts.However, the delayed timeline, announced in January, for submission of the application for clearance of the Enteric Protozoan test kit in the US was disappointing.The FDA submission is now expected before the end of April vs AGM guidance targeting December and our assumption of Q1 CY23.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Genetic Signatures (GSS) - FDA Clearance Remains Key Despite Submission Delay